William Blair Estimates Biogen's Q2 Earnings (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIB - Free Report) - Equities research analysts at William Blair cut their Q2 2025 earnings estimates for Biogen in a note issued to investors on Wednesday, April 23rd. William Blair analyst M. Minter now anticipates that the biotechnology company will post earnings of $4.10 per share for the quarter, down from their prior forecast of $4.20. William Blair has a "Outperform" rating on the stock. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. William Blair also issued estimates for Biogen's Q4 2025 earnings at $3.83 EPS and FY2026 earnings at $14.64 EPS.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.43 by $0.01. Biogen had a net margin of 16.87% and a return on equity of 14.98%.

BIIB has been the subject of a number of other research reports. Piper Sandler lowered their target price on Biogen from $135.00 to $115.00 and set a "neutral" rating for the company in a research note on Tuesday. Citigroup decreased their price objective on shares of Biogen from $160.00 to $145.00 and set a "neutral" rating for the company in a research report on Thursday, February 13th. Bank Of America (Bofa) dropped their target price on Biogen from $178.00 to $163.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 11th. Morgan Stanley reduced their price target on Biogen from $157.00 to $152.00 and set an "equal weight" rating for the company in a report on Wednesday, April 9th. Finally, HC Wainwright dropped their price objective on Biogen from $300.00 to $241.00 and set a "buy" rating on the stock in a report on Thursday, February 13th. Twenty equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $201.93.

Biogen Trading Up 0.9 %

Shares of NASDAQ:BIIB traded up $1.05 during trading on Monday, reaching $120.17. The stock had a trading volume of 1,003,166 shares, compared to its average volume of 1,346,010. Biogen has a fifty-two week low of $110.04 and a fifty-two week high of $238.00. The business has a fifty day moving average price of $132.12 and a 200-day moving average price of $148.38. The company has a quick ratio of 0.90, a current ratio of 1.35 and a debt-to-equity ratio of 0.27. The stock has a market cap of $17.59 billion, a P/E ratio of 10.74, a PEG ratio of 1.51 and a beta of 0.06.

Insider Buying and Selling at Biogen

In related news, Director Stephen A. Sherwin sold 8,760 shares of Biogen stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $150.02, for a total value of $1,314,175.20. Following the completion of the sale, the director now owns 11,318 shares in the company, valued at approximately $1,697,926.36. This trade represents a 43.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.16% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Biogen

Institutional investors and hedge funds have recently modified their holdings of the company. Pacer Advisors Inc. increased its stake in Biogen by 13,574.7% during the 4th quarter. Pacer Advisors Inc. now owns 2,667,531 shares of the biotechnology company's stock worth $407,919,000 after buying an additional 2,648,024 shares during the period. Norges Bank acquired a new position in Biogen during the 4th quarter worth $355,569,000. Van ECK Associates Corp raised its position in Biogen by 977.9% in the 4th quarter. Van ECK Associates Corp now owns 1,066,460 shares of the biotechnology company's stock valued at $163,083,000 after purchasing an additional 967,523 shares in the last quarter. Invesco Ltd. grew its position in shares of Biogen by 30.6% during the fourth quarter. Invesco Ltd. now owns 2,128,807 shares of the biotechnology company's stock worth $325,537,000 after buying an additional 499,074 shares in the last quarter. Finally, AQR Capital Management LLC increased its stake in shares of Biogen by 982.0% during the fourth quarter. AQR Capital Management LLC now owns 539,692 shares of the biotechnology company's stock worth $81,914,000 after buying an additional 489,811 shares during the period. Hedge funds and other institutional investors own 87.93% of the company's stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.